PURPOSE: Monitoring HER2 expression is crucial for selection of breast cancer patients amenable to HER2-targeting therapy. The Affibody molecule Z(HER2:342) binds to HER2 with picomolar affinity and enables specific imaging of HER2 expression. Previously, Z(HER2:342) with the additional N-terminal mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) sequence was labelled with (99m)Tc and demonstrated specific targeting of HER2-expressing xenografts. However, hepatobiliary excretion caused high radioactivity accumulation in the abdomen. We investigated whether the biodistribution of Z(HER2:342) can be improved by substituting glycyl residues in the chelating sequence with more hydrophilic seryl residues. METHODS: The Affibody molecule Z(HER2:342), carrying the chelators mercaptoacetyl-glycyl-seryl-glycyl (maGSG), mercaptoacetyl-glycyl-D: -seryl-glycyl [maG(D-S)G] and mercaptoacetyl-seryl-seryl-seryl (maSSS), were prepared by peptide synthesis and labelled with (99m)Tc. The differences in the excretion pathways were evaluated in normal mice. The tumour targeting capacity of (99m)Tc-maSSS-Z(HER2:342) was studied in nude mice bearing SKOV-3 xenografts and compared with the capacity of radioiodinated Z(HER2:342). RESULTS: A shift towards renal excretion was obtained when glycine was substituted with serine in the chelating sequence. The radioactivity in the gastrointestinal tract was reduced threefold for the maSSS conjugate in comparison with the maGGG conjugate 4 h post injection (p.i.). The tumour uptake of (99m)Tc-maSSS-Z(HER2:342) was 11.5 +/- 0.5% IA/g 4 h p.i., and the tumour-to-blood ratio was 76. The pharmacokinetics and uptake characteristics of technetium-labelled Z(HER2:342) were better than those of radioiodinated Z(HER2:342). CONCLUSION: The introduction of serine residues in the chelator results in better tumour imaging properties of the Affibody molecule Z(HER2:342) compared with glycyl-containing chelators and is favourable for imaging of tumours and metastases in the abdominal area.
PURPOSE: Monitoring HER2 expression is crucial for selection of breast cancerpatients amenable to HER2-targeting therapy. The Affibody molecule Z(HER2:342) binds to HER2 with picomolar affinity and enables specific imaging of HER2 expression. Previously, Z(HER2:342) with the additional N-terminal mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) sequence was labelled with (99m)Tc and demonstrated specific targeting of HER2-expressing xenografts. However, hepatobiliary excretion caused high radioactivity accumulation in the abdomen. We investigated whether the biodistribution of Z(HER2:342) can be improved by substituting glycyl residues in the chelating sequence with more hydrophilic seryl residues. METHODS: The Affibody molecule Z(HER2:342), carrying the chelators mercaptoacetyl-glycyl-seryl-glycyl (maGSG), mercaptoacetyl-glycyl-D: -seryl-glycyl [maG(D-S)G] and mercaptoacetyl-seryl-seryl-seryl (maSSS), were prepared by peptide synthesis and labelled with (99m)Tc. The differences in the excretion pathways were evaluated in normal mice. The tumour targeting capacity of (99m)Tc-maSSS-Z(HER2:342) was studied in nude mice bearing SKOV-3 xenografts and compared with the capacity of radioiodinated Z(HER2:342). RESULTS: A shift towards renal excretion was obtained when glycine was substituted with serine in the chelating sequence. The radioactivity in the gastrointestinal tract was reduced threefold for the maSSS conjugate in comparison with the maGGG conjugate 4 h post injection (p.i.). The tumour uptake of (99m)Tc-maSSS-Z(HER2:342) was 11.5 +/- 0.5% IA/g 4 h p.i., and the tumour-to-blood ratio was 76. The pharmacokinetics and uptake characteristics of technetium-labelled Z(HER2:342) were better than those of radioiodinated Z(HER2:342). CONCLUSION: The introduction of serine residues in the chelator results in better tumour imaging properties of the Affibody molecule Z(HER2:342) compared with glycyl-containing chelators and is favourable for imaging of tumours and metastases in the abdominal area.
Authors: Anna Orlova; Vladimir Tolmachev; Rikard Pehrson; Malin Lindborg; Thuy Tran; Mattias Sandström; Fredrik Y Nilsson; Anders Wennborg; Lars Abrahmsén; Joachim Feldwisch Journal: Cancer Res Date: 2007-03-01 Impact factor: 12.701
Authors: Rafael Molina; Vivian Barak; Arie van Dalen; Michael J Duffy; Roland Einarsson; Massimo Gion; Helenka Goike; Rolf Lamerz; Marius Nap; György Sölétormos; Petra Stieber Journal: Tumour Biol Date: 2005 Nov-Dec
Authors: Anna Orlova; Mikaela Magnusson; Tove L J Eriksson; Martin Nilsson; Barbro Larsson; Ingmarie Höidén-Guthenberg; Charles Widström; Jörgen Carlsson; Vladimir Tolmachev; Stefan Ståhl; Fredrik Y Nilsson Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701
Authors: Vladimir Tolmachev; Heng Xu; Helena Wållberg; Sara Ahlgren; Magnus Hjertman; Anna Sjöberg; Mattias Sandström; Lars Abrahmsén; Martin W Brechbiel; Anna Orlova Journal: Bioconjug Chem Date: 2008-07-12 Impact factor: 4.774
Authors: Torun Ekblad; Thuy Tran; Anna Orlova; Charles Widström; Joachim Feldwisch; Lars Abrahmsén; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev Journal: Eur J Nucl Med Mol Imaging Date: 2008-07-02 Impact factor: 9.236
Authors: Hanna Lindberg; Camilla Hofström; Mohamed Altai; Hadis Honorvar; Helena Wållberg; Anna Orlova; Stefan Ståhl; Torbjörn Gräslund; Vladimir Tolmachev Journal: Tumour Biol Date: 2012-01-17
Authors: Zhen Cheng; Omayra Padilla De Jesus; Daniel J Kramer; Abhijit De; Jack M Webster; Olivier Gheysens; Jelena Levi; Mohammad Namavari; Sen Wang; Jinha Mark Park; Rong Zhang; Hongguang Liu; Brian Lee; Faisal A Syud; Sanjiv Sam Gambhir Journal: Mol Imaging Biol Date: 2009-09-25 Impact factor: 3.488
Authors: Mohammad Namavari; Omayra Padilla De Jesus; Zhen Cheng; Abhijit De; Ernest Kovacs; Jelena Levi; Rong Zhang; Joshua K Hoerner; Hans Grade; Faisal A Syud; Sanjiv S Gambhir Journal: Mol Imaging Biol Date: 2008-05-15 Impact factor: 3.488
Authors: Thuy A Tran; Daniel Rosik; Lars Abrahmsén; Mattias Sandström; Anna Sjöberg; Helena Wållberg; Sara Ahlgren; Anna Orlova; Vladimir Tolmachev Journal: Eur J Nucl Med Mol Imaging Date: 2009-06-06 Impact factor: 9.236